Genmab A (GMAB) Non-Current Deferred Tax Liability (2024 - 2026)

Genmab A's Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $365.0 million for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 10.61% year-over-year to $365.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $365.0 million (up 10.61% YoY) and the FY2025 annual result came in at $364.0 million, up 10.3% from the prior year.
• Non-Current Deferred Tax Liability was $365.0 million for Q1 2026 at Genmab A, roughly flat from $364.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $365.0 million in Q1 2026 and bottomed at $330.0 million in Q4 2024.
• A 3-year average of $341.5 million and a median of $330.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability advanced 10.3% — and 2026, when it increased 10.61%.
• Genmab A's Non-Current Deferred Tax Liability stood at $330.0 million in 2024, then grew by 10.3% to $364.0 million in 2025, then rose by 0.27% to $365.0 million in 2026.
• Business Quant data shows GMAB's Non-Current Deferred Tax Liability at $365.0 million in Q1 2026, $364.0 million in Q4 2025, and $330.0 million in Q3 2025.